📊 BZYR Key Takeaways
Is Burzynski Research Institute Inc. (BZYR) a Good Investment?
Burzynski Research Institute is in critical financial distress with zero revenue, massive operating losses, severely depleted assets ($2.3K), and negative stockholders equity of -$67.3K. The company is technically insolvent with liabilities exceeding assets by $67.3K and insufficient cash ($2.2K) to support ongoing operations, making recovery highly unlikely.
The fundamentals are extremely weak: the company generated no revenue, posted a nearly $1.0 million net loss, and burned almost the same amount of cash from operations. With only about $2.2 thousand of cash, a 0.05x current ratio, and negative equity, the business appears financially distressed and dependent on external support rather than internally generated operating strength.
Burzynski Research Institute Inc. Key Strengths (BZYR)
- No strengths identified
- Reported liabilities are small in absolute dollar terms
- Capital expenditure needs appear minimal based on available cash flow data
- Losses were flat year over year rather than accelerating
BZYR Stock Risks: Burzynski Research Institute Inc. Investment Risks
- Zero revenue generation - complete loss of business operations
- Negative stockholders equity of -$67.3K indicates technical insolvency
- Massive liquidity crisis with current ratio of 0.05x and only $2.2K in cash
- Operating and free cash flows deeply negative at -$967.2K
- Total liabilities ($69.6K) far exceed total assets ($2.3K) by 30x
- Extreme negative ROA of -43893.2% indicates severe asset impairment
- No insider buying activity suggests loss of management confidence
- Inadequate working capital to support basic operations or debt service
- No revenue base, which makes profitability and business scalability highly questionable
- Severe liquidity weakness with minimal cash and a 0.05x current ratio
- Negative stockholders equity indicates balance sheet impairment and weak financial flexibility
Key Metrics to Watch
- Revenue generation or return to operations
- Stockholders equity - path to positive equity
- Cash position and sources of funding for operations
- Revenue generation and operating cash flow improvement
- Cash balance and stockholders equity restoration
Burzynski Research Institute Inc. (BZYR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BZYR Profit Margin, ROE & Profitability Analysis
BZYR vs Healthcare Sector: How Burzynski Research Institute Inc. Compares
How Burzynski Research Institute Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Burzynski Research Institute Inc. Stock Overvalued? BZYR Valuation Analysis 2026
Based on fundamental analysis, Burzynski Research Institute Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Burzynski Research Institute Inc. Balance Sheet: BZYR Debt, Cash & Liquidity
BZYR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Burzynski Research Institute Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
BZYR Revenue Growth, EPS Growth & YoY Performance
BZYR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | N/A | -$328.9K | $0.00 |
| Q2 2026 | N/A | -$331.5K | $0.00 |
| Q3 2025 | N/A | -$252.1K | $0.00 |
| Q2 2025 | N/A | -$252.1K | $0.00 |
| Q1 2025 | N/A | -$331.5K | $0.00 |
| Q3 2024 | N/A | -$215.9K | $0.00 |
| Q2 2024 | N/A | -$215.9K | $0.00 |
| Q1 2024 | N/A | -$231.7K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Burzynski Research Institute Inc. Dividends, Buybacks & Capital Allocation
BZYR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Burzynski Research Institute Inc. (CIK: 0000724445)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BZYR
What is the AI rating for BZYR?
Burzynski Research Institute Inc. (BZYR) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BZYR's key strengths?
Claude: . ChatGPT: Reported liabilities are small in absolute dollar terms. Capital expenditure needs appear minimal based on available cash flow data.
What are the risks of investing in BZYR?
Claude: Zero revenue generation - complete loss of business operations. Negative stockholders equity of -$67.3K indicates technical insolvency. ChatGPT: No revenue base, which makes profitability and business scalability highly questionable. Severe liquidity weakness with minimal cash and a 0.05x current ratio.
What is BZYR's revenue and growth?
Burzynski Research Institute Inc. reported revenue of $0.0.
Does BZYR pay dividends?
Burzynski Research Institute Inc. does not currently pay dividends.
Where can I find BZYR SEC filings?
Official SEC filings for Burzynski Research Institute Inc. (CIK: 0000724445) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BZYR's EPS?
Burzynski Research Institute Inc. has a diluted EPS of $-0.01.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BZYR's fundamental grade?
Based on our AI fundamental analysis in June 2026, Burzynski Research Institute Inc. has a D grade with 96% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BZYR stock overvalued or undervalued?
Valuation metrics for BZYR: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BZYR's AI grade for 2026?
Our dual AI analysis gives Burzynski Research Institute Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BZYR's free cash flow?
Burzynski Research Institute Inc.'s operating cash flow is $-967.2K, with capital expenditures of N/A.
How does BZYR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.05 (avg: 2).